A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis

医学 脂肪性肝炎 内科学 胃肠病学 脂肪肝 疾病
作者
Lung‐Yi Mak,Ed J. Gane,Christian Schwabe,Ki Tae Yoon,Jeong Heo,Russell S. Scott,Jeong‐Hoon Lee,Jung Il Lee,Young Oh Kweon,Martin Weltman,Stephen A. Harrison,Brent A. Neuschwander‐Tetri,Kenneth J. Cusi,Rohit Seth Loomba,Bruce D. Given,Dawn R. Christianson,Eric Garcia-Medel,Min Yi,James Hamilton,Man‐Fung Yuen
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:78 (4): 684-692 被引量:103
标识
DOI:10.1016/j.jhep.2022.11.025
摘要

•HSD17B13 loss-of-function mutations are protective against alcohol-related and non-alcoholic liver disease, including NASH. •ARO-HSD is a hepatocyte-targeted siRNA therapeutic designed to silence HSD17B13 expression. •ARO-HSD demonstrated a favorable safety profile in healthy volunteers and patients with suspected NASH. •Mean change from baseline at Day 71 in hepatic HSD17β13 mRNA was -93.4% (ARO-HSD 200 mg). •Mean change in alanine aminotransferase from baseline at Day 71 was ‑42.3% (ARO-HSD 200 mg). Background & Aims Loss-of-function HSD17β13 mutations protect against the development of chronic liver disease. HSD17β13 inhibition represents a potential approach to treat liver diseases, such as non-alcoholic steatohepatitis (NASH). ARO-HSD is an RNA interference (RNAi) therapeutic designed to selectively reduce expression of HSD17β13 mRNA in hepatocytes. In this study, we evaluated the effects of ARO-HSD in normal healthy volunteers (NHVs) and patients with confirmed or clinically suspected NASH. Methods The safety, tolerability, and pharmacodynamics of ARO-HSD were evaluated in 32 NHVs and 18 patients with confirmed/clinically suspected NASH. Double-blind NHV cohorts received single escalating doses of ARO-HSD (25, 50, 100, or 200 mg) or placebo subcutaneously on Day 1. Open-label patient cohorts received ARO-HSD (25, 100, or 200 mg) subcutaneously on Days 1 and 29. Liver biopsy was performed pre-dose and on Day 71 to evaluate expression levels of HSD17β13 mRNA and protein. Results ARO-HSD treatment was well tolerated with no treatment-related serious adverse events or drug discontinuations. The most frequently reported treatment-emergent adverse events were mild injection site reactions, which were short in duration. Mean changes in hepatic HSD17β13 mRNA from baseline to Day 71 were: -56.9% (25 mg), -85.5% (100 mg), and -93.4% (200 mg). The mean HSD17β13 mRNA reduction was 78.6% (p <0.0001) across pooled cohorts. Hepatic HSD17β13 protein levels were similarly reduced across doses. In patients, mean changes in alanine aminotransferase from baseline to Day 71 were -7.7% (25 mg), -39.3% (100 mg), and -42.3% (200 mg) (p <0.001 for pooled cohorts). Conclusions ARO-HSD was well tolerated at doses ≤200 mg. This proof-of-concept study demonstrated that short-term treatment with ARO-HSD reduces hepatic HSD17β13 mRNA and protein expression, which is accompanied by reductions in alanine aminotransferase. ClinicalTrials.gov number NCT04202354. Impacts and implications There is an unmet medical need for new therapies to treat alcohol-related and non-alcoholic liver disease. ARO-HSD is a small-interfering RNA designed to silence HSD17β13 expression and hence to phenocopy the protective effect seen in individuals with HSD17β13 loss-of-function. The reductions in HSD17β13 expression and in transaminases seen with ARO-HSD administration represent an initial step towards clinical validation of HSD17β13, a drug target with substantial genetic validation, as an important modulator of human liver disease. Loss-of-function HSD17β13 mutations protect against the development of chronic liver disease. HSD17β13 inhibition represents a potential approach to treat liver diseases, such as non-alcoholic steatohepatitis (NASH). ARO-HSD is an RNA interference (RNAi) therapeutic designed to selectively reduce expression of HSD17β13 mRNA in hepatocytes. In this study, we evaluated the effects of ARO-HSD in normal healthy volunteers (NHVs) and patients with confirmed or clinically suspected NASH. The safety, tolerability, and pharmacodynamics of ARO-HSD were evaluated in 32 NHVs and 18 patients with confirmed/clinically suspected NASH. Double-blind NHV cohorts received single escalating doses of ARO-HSD (25, 50, 100, or 200 mg) or placebo subcutaneously on Day 1. Open-label patient cohorts received ARO-HSD (25, 100, or 200 mg) subcutaneously on Days 1 and 29. Liver biopsy was performed pre-dose and on Day 71 to evaluate expression levels of HSD17β13 mRNA and protein. ARO-HSD treatment was well tolerated with no treatment-related serious adverse events or drug discontinuations. The most frequently reported treatment-emergent adverse events were mild injection site reactions, which were short in duration. Mean changes in hepatic HSD17β13 mRNA from baseline to Day 71 were: -56.9% (25 mg), -85.5% (100 mg), and -93.4% (200 mg). The mean HSD17β13 mRNA reduction was 78.6% (p <0.0001) across pooled cohorts. Hepatic HSD17β13 protein levels were similarly reduced across doses. In patients, mean changes in alanine aminotransferase from baseline to Day 71 were -7.7% (25 mg), -39.3% (100 mg), and -42.3% (200 mg) (p <0.001 for pooled cohorts). ARO-HSD was well tolerated at doses ≤200 mg. This proof-of-concept study demonstrated that short-term treatment with ARO-HSD reduces hepatic HSD17β13 mRNA and protein expression, which is accompanied by reductions in alanine aminotransferase.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
loii的应助被科研通管家采纳,获得10
刚刚
搜集达人的应助被科研通管家采纳,获得10
刚刚
在水一方的应助被科研通管家采纳,获得20
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
所所的应助被科研通管家采纳,获得10
1秒前
科研通AI65的应助被科研通管家采纳,获得10
1秒前
1秒前
我是老大的应助被科研通管家采纳,获得10
1秒前
CipherSage的应助被科研通管家采纳,获得10
1秒前
Lucas的应助被科研通管家采纳,获得10
1秒前
FashionBoy的应助被小乐采纳,获得10
2秒前
明哲派完成签到,获得积分10
2秒前
领导范儿的应助被笑点低明轩采纳,获得10
2秒前
zxy发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
独孤求败发布了新的文献求助10
5秒前
典雅浩轩完成签到,获得积分10
6秒前
可爱的函函的应助被cc采纳,获得30
7秒前
可爱的函函的应助被YunJi采纳,获得10
7秒前
Mole发布了新的文献求助10
8秒前
科研助手发布了新的文献求助10
8秒前
enen驳回了打打的应助
8秒前
鹅黄色的丹桂完成签到,获得积分10
10秒前
王WWWWWWWW发布了新的文献求助10
10秒前
隐形曼青的应助被纾寒采纳,获得10
11秒前
11秒前
老实凝蕊完成签到,获得积分10
11秒前
艺术人生完成签到,获得积分10
12秒前
13秒前
科研通AI6.3的应助被李南采纳,获得10
15秒前
无花果的应助被tsl采纳,获得10
16秒前
ooo发布了新的文献求助10
16秒前
hooz发布了新的文献求助20
16秒前
18秒前
wanci的应助被符聪采纳,获得10
18秒前
素人渔夫完成签到,获得积分10
18秒前
万能图书馆的应助被lucas采纳,获得10
20秒前
金乌完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189584
求助须知:如何正确求助?哪些是违规求助? 9576880
关于积分的说明 21849988
捐赠科研通 7787473
什么是DOI,文献DOI怎么找? 3435679
关于科研通互助平台的介绍 2559801
邀请新用户注册赠送积分活动 2482606